Women are still underrepresented in heart drug trials
Pivotal clinical trials that are used to win US marketing approval for many new heart drugs don't include enough women to clearly assess gender differences, a recent study suggests.
This is because fewer women than men are invited to participate.
Over the study period, the mean percentage of women participants was 34% (ranging from 22% to 81%) across different cardiovascular areas.
This is problematic, say the authors, because there are sex and gender differences in how heart disease impacts the body, symptoms and treatment outcomes.